8YLS
 
 | | Structure of SARS-CoV-2 Mpro in complex with its degrader | | 分子名称: | (4-methoxyphenyl)methyl ~{N}-[(2~{S})-4-methyl-1-oxidanylidene-1-[[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate, 3C-like proteinase nsp5 | | 著者 | Feng, Y, Li, W, Cheng, S.H, Li, X.B. | | 登録日 | 2024-03-06 | | 公開日 | 2024-09-04 | | 実験手法 | X-RAY DIFFRACTION (1.93 Å) | | 主引用文献 | The Main Protease Degraders: Potent Broad-Spectrum Agents for Anti-Coronavirus Agents
To Be Published
|
|
6ZFO
 | | Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, EY6A heavy chain, EY6A light chain, ... | | 著者 | Duyvesteyn, H.M.E, Zhou, D, Zhao, Y, Fry, E.E, Ren, J, Stuart, D.I. | | 登録日 | 2020-06-17 | | 公開日 | 2020-07-08 | | 最終更新日 | 2021-12-22 | | 実験手法 | ELECTRON MICROSCOPY (4.4 Å) | | 主引用文献 | Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Nat.Struct.Mol.Biol., 27, 2020
|
|
6ZDH
 | | SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, EY6A heavy chain, ... | | 著者 | Duyvesteyn, H.M.E, Zhou, D, Zhao, Y, Fry, E.E, Ren, J, Stuart, D.I. | | 登録日 | 2020-06-14 | | 公開日 | 2020-07-01 | | 最終更新日 | 2021-12-22 | | 実験手法 | ELECTRON MICROSCOPY (3.7 Å) | | 主引用文献 | Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Nat.Struct.Mol.Biol., 27, 2020
|
|
6ZCZ
 | | Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody. | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, EY6A heavy chain, ... | | 著者 | Zhou, D, Zhao, Y, Fry, E.E, Ren, J, Stuart, D.I. | | 登録日 | 2020-06-12 | | 公開日 | 2020-06-24 | | 最終更新日 | 2024-01-24 | | 実験手法 | X-RAY DIFFRACTION (2.65 Å) | | 主引用文献 | Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Nat.Struct.Mol.Biol., 27, 2020
|
|
6ZDG
 | | Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, EY6A heavy chain, EY6A light chain, ... | | 著者 | Duyvesteyn, H.M.E, Zhou, D, Zhao, Y, Fry, E.E, Ren, J, Stuart, D.I. | | 登録日 | 2020-06-14 | | 公開日 | 2020-07-29 | | 最終更新日 | 2021-12-22 | | 実験手法 | ELECTRON MICROSCOPY (4.7 Å) | | 主引用文献 | Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Nat.Struct.Mol.Biol., 27, 2020
|
|
6ZER
 | | Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, EY6A heavy chain, EY6A light chain, ... | | 著者 | Zhou, D, Zhao, Y, Fry, E.E, Ren, J, Stuart, D.I. | | 登録日 | 2020-06-16 | | 公開日 | 2020-06-24 | | 最終更新日 | 2024-01-24 | | 実験手法 | X-RAY DIFFRACTION (3.8 Å) | | 主引用文献 | Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Nat.Struct.Mol.Biol., 27, 2020
|
|
7PQY
 | | Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with FI-3A Fab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, FI-3A Fab heavy chain, FI-3A Fab light chain, ... | | 著者 | Zhou, D, Ren, J, Stuart, D. | | 登録日 | 2021-09-20 | | 公開日 | 2022-02-02 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (3 Å) | | 主引用文献 | Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
Theranostics, 12, 2022
|
|
7PQZ
 | | Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with FI-3A and FD-11A Fabs | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, FD-11A Fab heavy chain, FD-11A Fab light chain, ... | | 著者 | Zhou, D, Ren, J, Stuart, D.I. | | 登録日 | 2021-09-20 | | 公開日 | 2022-02-02 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (3.2 Å) | | 主引用文献 | Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
Theranostics, 12, 2022
|
|
7PR0
 | | Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with FD-5D Fab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, FD-5D Fab heavy chain, ... | | 著者 | Zhou, D, Ren, J, Stuart, D.I. | | 登録日 | 2021-09-20 | | 公開日 | 2022-02-02 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (2.92 Å) | | 主引用文献 | Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
Theranostics, 12, 2022
|
|
7Q0A
 | | SARS-CoV-2 Spike ectodomain with Fab FI3A | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, FI3A fab Light chain, ... | | 著者 | Duyvesteyn, H.M.E, Ren, J, Stuart, D.I. | | 登録日 | 2021-10-14 | | 公開日 | 2022-02-23 | | 実験手法 | ELECTRON MICROSCOPY (4.8 Å) | | 主引用文献 | Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
Theranostics, 12, 2022
|
|
8YRP
 | | SARS-CoV-2 Delta Spike in complex with JM-1A | | 分子名称: | JM-1A Heavy Chain, JM-1A Light Chain, Spike glycoprotein | | 著者 | Nguyen, V.H.T, Chen, X. | | 登録日 | 2024-03-21 | | 公開日 | 2024-06-05 | | 最終更新日 | 2024-06-26 | | 実験手法 | ELECTRON MICROSCOPY (3.64 Å) | | 主引用文献 | The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.
Plos Pathog., 20, 2024
|
|
8YRO
 | | SARS-CoV-2 Delta Spike in complex with JL-8C | | 分子名称: | JL-8C Heavy Chain, JL-8C Light Chain, Spike glycoprotein | | 著者 | Nguyen, V.H.T, Chen, X. | | 登録日 | 2024-03-21 | | 公開日 | 2024-06-05 | | 最終更新日 | 2024-06-26 | | 実験手法 | ELECTRON MICROSCOPY (3.27 Å) | | 主引用文献 | The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.
Plos Pathog., 20, 2024
|
|
8YZ5
 | | SARS-CoV-2 Delta Spike in complex with Fab of JE-5C | | 分子名称: | Fab heavy chain of JE-5C, Fab light chain of JE-5C, Spike glycoprotein | | 著者 | Chen, X, Wu, Y.-M. | | 登録日 | 2024-04-06 | | 公開日 | 2024-06-05 | | 最終更新日 | 2024-06-26 | | 実験手法 | ELECTRON MICROSCOPY (3.93 Å) | | 主引用文献 | The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.
Plos Pathog., 20, 2024
|
|
8YZ6
 | | SARS-CoV-2 Spike (BA.1) in complex with Fab of JH-8B | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Fab heavy chain of JH-8B, ... | | 著者 | Chen, X, Wu, Y.-M. | | 登録日 | 2024-04-06 | | 公開日 | 2024-06-05 | | 最終更新日 | 2024-06-26 | | 実験手法 | ELECTRON MICROSCOPY (4.55 Å) | | 主引用文献 | The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.
Plos Pathog., 20, 2024
|
|
8X0X
 | | Crystal structure of JE-5C in complex with SARS-CoV-2 RBD | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Heavy chain of JE-5C Fab, Light chain of JE-5C Fab, ... | | 著者 | Mohapatra, A, Chen, X. | | 登録日 | 2023-11-06 | | 公開日 | 2024-06-05 | | 最終更新日 | 2024-07-03 | | 実験手法 | X-RAY DIFFRACTION (3.45 Å) | | 主引用文献 | The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.
Plos Pathog., 20, 2024
|
|
8X0Y
 | | Crystal structure of JM-1A in complex with SARS-CoV-2 RBD | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, Heavy chain of JM-1A Fab, ... | | 著者 | Mohapatra, A, Chen, X. | | 登録日 | 2023-11-06 | | 公開日 | 2024-06-05 | | 最終更新日 | 2024-07-03 | | 実験手法 | X-RAY DIFFRACTION (1.94 Å) | | 主引用文献 | The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.
Plos Pathog., 20, 2024
|
|
